Quick Summary:
Understanding the rapidly evolving STD Testing market and its potential growth projection is cardinal for strategic business decision-making. Expected to reach an estimated worth of US$144.8 Billion by 2030, an amplified focus on sexual health and disease prevention is driving the industry on a global scale. Deciphering the market dynamics is essential to stay competitive and make informed investments in this lucrative sector.
Our comprehensive market research report provides in-depth analysis of key segments, including Chlamydia and Herpes Simplex Virus, serving a rigorous understanding of their progress and projected growth rates. Highlighting geographic breakdowns, the report also provides insights into significant markets such as the U.S., China, Japan, Canada, and Germany. Additionally, it features an extensive and comparative overview of leading competitors in the STD Testing market. This report functions as your strategic compass, guiding crucial decisions for both present and future business prospects.
Global STD Testing Market to Reach $144.8 Billion by 2030
The global market for STD Testing estimated at US$97.3 Billion in the year 2022, is projected to reach a revised size of US$144.8 Billion by 2030, growing at a CAGR of 5.1% over the analysis period 2022-2030. Chlamydia, one of the segments analyzed in the report, is projected to record 4.9% CAGR and reach US$40.6 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Herpes Simplex Virus segment is readjusted to a revised 5.9% CAGR for the next 8-year period.
The U.S. Market is Estimated at $26.3 Billion, While China is Forecast to Grow at 8.1% CAGR
The STD Testing market in the U.S. is estimated at US$26.3 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$31.5 Billion by the year 2030 trailing a CAGR of 8.1% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.8% and 4.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.Select Competitors (Total 47 Featured) -
- Alere, Inc.
- Becton, Dickinson and Company
- bioMerieux SA
- Danaher Corporation
- F. Hoffmann-La Roche AG
- Hologic, Inc.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and the publisher's Research Platform
- Complimentary updates for one year
Frequently Asked Questions about the Global Market for STD Testing
What is the estimated value of the Global Market for STD Testing?
The Global Market for STD Testing was estimated to be valued at $97.3 Billion in 2022.
What is the growth rate of the Global Market for STD Testing?
The growth rate of the Global Market for STD Testing is 5.1%, with an estimated value of $144.8 Billion by 2030.
What is the forecasted size of the Global Market for STD Testing?
The Global Market for STD Testing is estimated to be worth $144.8 Billion by 2030.
Who are the key companies in the Global Market for STD Testing?
Key companies in the Global Market for STD Testing include Alere, Inc., Becton, Dickinson and Company, bioMerieux SA, Danaher Corporation, F. Hoffmann, La Roche AG and Hologic, Inc..
| Report Attribute | Details |
|---|---|
| No. of Pages | 197 |
| Published | December 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 97.3 Billion |
| Forecasted Market Value ( USD | $ 144.8 Billion |
| Compound Annual Growth Rate | 5.1% |
| Regions Covered | Global |
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- STD Testing - Global Key Competitors Percentage Market Share in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World STD Testing Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
- Table 2: World Recent Past, Current & Future Analysis for STD Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 3: World Historic Review for STD Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 4: World 16-Year Perspective for STD Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
- Table 5: World Recent Past, Current & Future Analysis for Chlamydia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 6: World Historic Review for Chlamydia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 7: World 16-Year Perspective for Chlamydia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 8: World Recent Past, Current & Future Analysis for Herpes Simplex Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 9: World Historic Review for Herpes Simplex Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 10: World 16-Year Perspective for Herpes Simplex Virus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 11: World Recent Past, Current & Future Analysis for Gonorrhea by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 12: World Historic Review for Gonorrhea by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 13: World 16-Year Perspective for Gonorrhea by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 14: World Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 15: World Historic Review for Human Papillomavirus (HPV) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 16: World 16-Year Perspective for Human Papillomavirus (HPV) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 17: World Recent Past, Current & Future Analysis for Syphilis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 18: World Historic Review for Syphilis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 19: World 16-Year Perspective for Syphilis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 20: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 21: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 22: World 16-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 23: World Recent Past, Current & Future Analysis for Laboratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 24: World Historic Review for Laboratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 25: World 16-Year Perspective for Laboratory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 26: World Recent Past, Current & Future Analysis for Point-of-Care (POC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 27: World Historic Review for Point-of-Care (POC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 28: World 16-Year Perspective for Point-of-Care (POC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
III. MARKET ANALYSIS
- UNITED STATES
- STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 29: USA Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 30: USA Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 31: USA 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2023 & 2030
- Table 32: USA Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 33: USA Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 34: USA 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
- CANADA
- Table 35: Canada Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 36: Canada Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 37: Canada 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2023 & 2030
- Table 38: Canada Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 39: Canada Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 40: Canada 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
- JAPAN
- STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 41: Japan Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 42: Japan Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 43: Japan 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2023 & 2030
- Table 44: Japan Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 45: Japan Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 46: Japan 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
- CHINA
- STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 47: China Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 48: China Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 49: China 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2023 & 2030
- Table 50: China Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 51: China Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 52: China 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
- EUROPE
- STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 53: Europe Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 54: Europe Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 55: Europe 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2023 & 2030
- Table 56: Europe Recent Past, Current & Future Analysis for STD Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 57: Europe Historic Review for STD Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 58: Europe 16-Year Perspective for STD Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
- Table 59: Europe Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 60: Europe Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 61: Europe 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
- FRANCE
- STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 62: France Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 63: France Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 64: France 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2023 & 2030
- Table 65: France Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 66: France Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 67: France 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
- GERMANY
- STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 68: Germany Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 69: Germany Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 70: Germany 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2023 & 2030
- Table 71: Germany Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 72: Germany Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 73: Germany 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
- ITALY
- Table 74: Italy Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 75: Italy Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 76: Italy 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2023 & 2030
- Table 77: Italy Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 78: Italy Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 79: Italy 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
- UNITED KINGDOM
- STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 80: UK Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 81: UK Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 82: UK 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2023 & 2030
- Table 83: UK Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 84: UK Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 85: UK 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
- SPAIN
- Table 86: Spain Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 87: Spain Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 88: Spain 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2023 & 2030
- Table 89: Spain Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 90: Spain Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 91: Spain 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
- RUSSIA
- Table 92: Russia Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 93: Russia Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 94: Russia 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2023 & 2030
- Table 95: Russia Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 96: Russia Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 97: Russia 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
- REST OF EUROPE
- Table 98: Rest of Europe Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 99: Rest of Europe Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 100: Rest of Europe 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2023 & 2030
- Table 101: Rest of Europe Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 102: Rest of Europe Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 103: Rest of Europe 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
- ASIA-PACIFIC
- STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 104: Asia-Pacific Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 105: Asia-Pacific Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 106: Asia-Pacific 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2023 & 2030
- Table 107: Asia-Pacific Recent Past, Current & Future Analysis for STD Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 108: Asia-Pacific Historic Review for STD Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 109: Asia-Pacific 16-Year Perspective for STD Testing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
- Table 110: Asia-Pacific Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 111: Asia-Pacific Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 112: Asia-Pacific 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
- AUSTRALIA
- STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
- INDIA
- STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
- SOUTH KOREA
- REST OF ASIA-PACIFIC
- LATIN AMERICA
- STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
- ARGENTINA
- BRAZIL
- MEXICO
- REST OF LATIN AMERICA
- MIDDLE EAST
- STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
- IRAN
- ISRAEL
- SAUDI ARABIA
- UNITED ARAB EMIRATES
- REST OF MIDDLE EAST
- AFRICA
- STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
Companies Mentioned
A selection of companies mentioned in this report includes:
- Alere, Inc.
- Becton, Dickinson and Company
- bioMerieux SA
- Danaher Corporation
- F. Hoffmann-La Roche AG
- Hologic, Inc.
